PUBLISHER: The Business Research Company | PRODUCT CODE: 1957642
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957642
Pharmacogenetic testing involves genetic analysis that reveals how a person's genes affect their response to particular drugs, enabling customized medication strategies for improved effectiveness and fewer adverse effects. This individualized method improves patient outcomes by aligning treatments with genetic characteristics. It finds broad application in areas like oncology, psychiatry, and cardiology.
The primary types of pharmacogenetic testing include whole genome sequencing, whole exome sequencing, array-based tests, and single gene tests. Whole genome sequencing offers a thorough approach to examining an organism's full genome. It sequences all DNA in one test, delivering a detailed view of a person's genetic profile. Drug types encompass prescription medications, nutraceuticals, recreational drugs, herbal supplements, vitamins, and over-the-counter drugs across various therapeutic fields like cardiology, gastroenterology, anesthesiology, genomics, endocrinology, immunology and hypersensitivity, dermatology, gynecology, oncology, and more. These are available via hospital pharmacies, retail pharmacies, mail-order pharmacies, and direct-to-consumer channels, serving end users such as healthcare providers, pharmaceutical and biotechnology firms, research centers, academic institutions, and others.
Tariffs have impacted the pharmacogenetic testing market by raising the cost of imported sequencing instruments, reagents, and assay components used in genetic analysis. These effects are most pronounced in Asia Pacific and emerging markets that rely heavily on imported diagnostic technologies. Rising tariff related costs have increased testing expenses and influenced laboratory investment decisions. This has affected the pace of pharmacogenetic test adoption in clinical and research settings. However, tariffs are also supporting the development of domestic diagnostic manufacturing, local assay production, and stronger regional testing ecosystems over time.
The pharmacogenetic testing market research report is one of a series of new reports from The Business Research Company that provides pharmacogenetic testing market statistics, including pharmacogenetic testing industry global market size, regional shares, competitors with a pharmacogenetic testing market share, detailed pharmacogenetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenetic testing industry. This pharmacogenetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharmacogenetic testing market size has grown rapidly in recent years. It will grow from $14.33 billion in 2025 to $16.58 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to advances in genomic sequencing technologies, adverse drug reaction concerns, rising chronic disease burden, declining genetic testing costs, increased clinical awareness.
The pharmacogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $29.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to growth of precision healthcare, expansion of direct-to-consumer testing, integration with electronic health records, increasing regulatory support, rising investment in genomics research. Major trends in the forecast period include rising adoption of personalized medicine, increasing use of genetic testing in drug selection, expansion of oncology and cardiology applications, growing demand for precision diagnostics, integration of pharmacogenomics in clinical practice.
The rising demand for personalized medicine is anticipated to fuel the expansion of the pharmacogenetic testing market in the future. Personalized medicine, also known as precision medicine, involves a medical strategy that customizes treatments and decisions based on a person's distinct genetic, biological, and lifestyle factors. This demand is growing because it enhances treatment effectiveness, enables earlier detection, and boosts cost-efficiency in healthcare. Pharmacogenetic testing aids personalized medicine by examining a patient's genetic makeup to forecast drug responses, allowing for better treatment choices and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based non-profit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Thus, the growing need for personalized medicine is propelling the pharmacogenetic testing market forward.
Major companies in the pharmacogenetics testing market are prioritizing the development of sophisticated pharmacogenomics testing services, including prescription-based pharmacogenetic testing, to boost medication safety, enhance treatment accuracy, and facilitate personalized therapeutic choices. Prescription-based pharmacogenetic testing involves genetic testing prescribed by qualified healthcare providers to assess how a person's genetic profile affects their response to particular drugs, enabling doctors to refine drug selection and dosage to lower the risk of adverse reactions. For example, in May 2023, UCSF, a US-based healthcare provider, introduced its pharmacogenomics testing service to increase the precision of medical treatments, offering clinicians genetic data that allows them to customize drug therapies to individual patient profiles, boost drug effectiveness, and reduce the chance of serious side effects.
In May 2023, HealthOme-a US-based company focused on advanced genetic testing and personalized medicine-acquired Kailos Genetics for an undisclosed sum. The deal bolsters HealthOme's personalized medicine offerings by incorporating Kailos Genetics' cutting-edge genomic technologies and pharmacogenetic expertise. It also amplifies HealthOme's capacity to provide full-spectrum precision-testing services via deeper knowledge in genomic analysis and tailored treatment recommendations. Kailos Genetics, a US-based firm, delivers pharmacogenetic testing via its Inspexion platform.
Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC
Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pharmacogenetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharmacogenetic testing market consists of revenues earned by entities by providing services such as predicting drug efficacy, guiding dosage selection, and preventing adverse drug reactions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmacogenetic testing market also includes sales of gene panels, deoxyribonucleic acid (DNA) sequencers, and home testing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharmacogenetic Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pharmacogenetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pharmacogenetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmacogenetic testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.